| 1.06 -0.14 (-11.67%) | 10-09 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 2.3  |
1-year : | 2.99 |
| Resists | First : | 1.97 |
Second : | 2.55 |
| Pivot price | 1.38 |
|||
| Supports | First : | 1.01 |
Second : | 0.84 |
| MAs | MA(5) : | 1.17 |
MA(20) : | 1.44 |
| MA(100) : | 2.26 |
MA(250) : | 2.89 |
|
| MACD | MACD : | -0.2 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 6.5  |
D(3) : | 4.9 |
| RSI | RSI(14): 31.8 |
|||
| 52-week | High : | 5.07 | Low : | 0.99 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ LSTA ] has closed below the lower bollinger band by 2.5%. Although price has broken the lower band and a downside breakout is possible; the most likely direction for [ LSTA ] is to continue within current trading range. Bollinger Bands are 32.9% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 1.28 - 1.29 | 1.29 - 1.3 |
| Low: | 1 - 1.01 | 1.01 - 1.02 |
| Close: | 1.05 - 1.06 | 1.06 - 1.07 |
Lisata Therapeutics, Inc. is a clinical-stage biopharmaceutical firm focused on pioneering and bringing to market cellular therapies. These treatments are designed to either reverse disease progression or facilitate the repair of damaged bodily tissues. The company's product portfolio features several notable candidates: HONEDRA, which has received SAKIGAKE designation and is presently in Phase II clinical trials for critical limb ischemia; XOWNA, currently undergoing Phase IIb testing for coronary microvascular dysfunction; and CLBS201, a CD34+ cell therapy aimed at individuals with chronic kidney disease who are not yet on dialysis. Founded in 1980 and based in Basking Ridge, New Jersey, the company was initially known as NeoStem, Inc., then rebranded as Caladrius Biosciences, Inc. in June 2015, before assuming its present identity as Lisata Therapeutics, Inc. on September 15, 2022.
Thu, 08 Oct 2026
Lisata Therapeutics Announces New Method of Use Patent - GlobeNewswire
Thu, 08 Oct 2026
A new cancer-treatment patent adds market exclusivity into 2043, Lisata says. - Stock Titan
Thu, 08 Oct 2026
Lisata Therapeutics wins new US patent for pancreatic cancer drug - Proactive financial news
Mon, 05 Oct 2026
Lisata Therapeutics, Inc. (LSTA) Stock Price, News, Quote & History - Yahoo! Finance Canada
Mon, 05 Oct 2026
Marea Therapeutics, a Subsidiary of Lisata Therapeutics, - GlobeNewswire
Mon, 05 Oct 2026
A rare hormone disorder trial doses its first patient; its drug may allow shots every two weeks, not daily. - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 11 (M) |
| Held by Insiders | 6.6e+006 (%) |
| Held by Institutions | 22.2 (%) |
| Shares Short | 142 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -1.636e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -16 % |
| Return on Assets (ttm) | 426 % |
| Return on Equity (ttm) | -56.8 % |
| Qtrly Rev. Growth | 100000 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | -108.15 |
| EBITDA (p.s.) | 106383 |
| Qtrly Earnings Growth | -1.7 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -12 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 118.4 |
| Price to Book value | 0 |
| Price to Sales | -0.01 |
| Price to Cash Flow | 1.1 |
| Dividend | 0 |
| Forward Dividend | 39410 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|